Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge
Launched by TAIWAN CARBON NANO TECHNOLOGY CORPORATION · Sep 26, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a device called the Ainos Flora Women's Vaginal Health Tester, which aims to help detect vaginal infections more accurately. The goal is to train a computer program to recognize signs of these infections based on vaginal discharge. If you're a female between the ages of 20 and 50, have had sexual experience, and can give your consent, you might be eligible to participate in this study.
If you join the trial, you'll undergo some assessments to help test the device. However, please note that you cannot participate if you are currently menstruating, have washed your vagina within the last three days, or have received treatment for a vaginal infection in the past week. The study is actively recruiting participants, and your involvement could contribute to important advancements in women's health.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female, Age ≥20 to ≤50.
- • Have had sexual experience.
- • Fully understand the subject's informed consent process and be willing to undergo all study-related assessments and procedures.
- Exclusion Criteria:
- Women who meet any of the following criteria by participant report will be excluded from the study:
- • During menstruation.
- • Have performed vaginal washing within three days.
- • Have been treated for vaginal infections within one week.
About Taiwan Carbon Nano Technology Corporation
Taiwan Carbon Nano Technology Corporation is a leading innovator in the field of nanotechnology, specializing in the research and development of carbon-based materials for various applications, including advanced medical therapies. The company is dedicated to advancing healthcare solutions through the integration of cutting-edge nanomaterials in clinical research and trials. With a strong commitment to quality, safety, and efficacy, Taiwan Carbon Nano Technology Corporation aims to enhance patient outcomes by leveraging its expertise in nanotechnology to develop novel therapeutic agents and delivery systems. Through strategic collaborations and rigorous scientific inquiry, the corporation strives to push the boundaries of medical innovation and contribute significantly to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Taipei, , Taiwan
Patients applied
Trial Officials
Dr. Fung-Wei Chang
Principal Investigator
Tri-Service General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials